Shl Telemedicine Ltd. · SIX:SHLTN
Shl Telemedicine — FY2022 Earnings Presentation
19 slides from Shl Telemedicine's earnings presentation, 2023
Slide 1: SHL Telemedicine FY Results 2022 Presentation
SHL Telemedicine FY Results 2022 Presentation
Slide 2: Forward looking statements
Forward looking statements This presentation was prepared for the purpose of providing and presenting information in a summary only and cannot replace a review of the reports of SHL Telemedicine (hereinafter: "the Company"). Many of the statements included in this presentation, as well as oral state
Slide 3: SHL Telemedicine at a glance
SHL Telemedicine at a glance 3M interactions and data Nasdaq: SHLT Listed on readings per year Swiss Stock Exchange: 30 SHLTN Telemedicine centers in Israel and Germany Significant strategic partners in the US market 27% increase Years of knowledge SHL is a leading provider and 24/7 telehealth in 20
Slide 4: Senior management
Senior management Yariv Alroy Ehud Barak Erez Nachtomy Amir Hai Co-Chairman Co-Chairman CEO CFO Former Prime Minister of Israel Yossi Vadnagra Linus Drop Bernd Altpeter Jason Bottiglieri General Manager Managing Director Managing Director General Manager SHL SHL Israel SHL Germany SHL Germany Teleme
Slide 5: 2021-2022: "we said and we delivered" in all territories
2021-2022: “we said and we delivered” in all territories 5
Slide 6: 2022 overview – Financial data
2022 overview – Financial data (*) Adjusted CASH REVENUES EBITDA(**) On Hand $59m $4.1m Currently 27% 35% ~$30m Operational R&D Cash Flow Gross Expenses CASH On HAND Break Even level $7.2m $18.7m Same as 2021 31 December 2022 )*( compared to 2021 in constant currency, Please see Supplemental Informa
Slide 7: Germany – Telemedicine becoming Standard of care
Germany – Telemedicine Adjusted becoming Standard of care EBITDA(*) Population of 82 million insureds Four Break even largest Health Insurance each serve 5-10 million insureds Revenues down due to loss of significant REVENUES chronic contract to Philips in 2021, and delay in implementing new materia
Slide 8: Germany – Back to growth
Germany – Back to growth SHL is the market leader in Germany and operates in a B2B model - managing and stabilizing chronic patients and saving costs for health insurers The company has agreements with leading health insurers, covering about 30% of the German health insurance market (about 25 millio
Slide 9: Germany – Virtual Visit service: Penetrating a market of about 800 million annual physical doctor visits
Germany – Virtual Visit service: Penetrating a market of about 800 million annual physical doctor visits In Germany - an average of 10 physical visits per person to a doctor each year (*) Won a pan-European tender published by BARMER in summer of 2022 for the virtual visit service - a new 7-year con
Slide 10: USA - Penetration through unique technology
USA - Penetration through unique technology Thousands of SmartHeart units already in use A unique personal full 12 Lead ECG, FDA cleared, in hospital REVENUES Adjusted quality (12 Lead is the Gold Standard) within 30 seconds, EBITDA(*) without the assistance of a medical professional. From anywhere
Slide 11: USA - faster progress than planned
USA - faster progress than planned Appointed CEO for SHL USA Increase in uses of the with increased activity in all Already FDA cleared SmartHeart platform channels 510(k) process for OTC clearance 11
Slide 12: Israel – High contribution to the company's profitability and cash flow
Israel – High contribution to the company's profitability and cash flow Revenues Adjusted B2C model EBITDA about$40 $45.1m (*) Average monthly fees $12.6m About 50,000 51% 25% Subscribers on service 6 years – average subscription length B2B model: Over 100 institutional customers sale of cardiac mon
Slide 13: Financials – P&L (in million)
Financials – P&L (in million) Revenue In USD million 64,000 60,000 56,000 (except per share amount) FY 2022 FY 2021cc* 52,000 48,000 44,000 40,000 Revenue for the period 59.0 46.4 36,000 32,000 28,000 24,000 Revenue by territories 20,000 2021 2022 Germany 13.4 16.0 R&D Gross Expenses Israel 45.1 30.
Slide 14: Financials – Balance Sheet and Cash Flow (in millions)
Financials – Balance Sheet and Cash Flow (in millions) In USD million FY 2022 FY2021 Cash and cash equivalents(*) 4.5 14.8 Short term bank investments 14.2 17.2 Total Assets Total cash and short-term investments 18.7 32.0 140 Short term bank debt 2.2 1.8 120 100 Long term bank debts 13.0 17.2 80 60
Slide 15: 2021-2022: "we said and we delivered" in all territories
2021-2022: “we said and we delivered” in all territories 15
Slide 16: 2023 – expected events
2023 – expected events Publication of results study for use of constant increase in the use of Virtual Visits Continued implementation of B2B model – Tier 1 customers Agreements with additional Obtain FDA OTC clearance Increased profitability health funds for Virtual Visit Start of B2C sales service
Slide 17: Thank You
Thank You SHL telemedicine * SHL sma theart Telemedicine
Slide 18: Supplement Information
Supplement Information Reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures In the table below, 2021 results have been presented at 2022 Key figures (as reported): constant cu
Slide 19: Supplement Information
Supplement Information Reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit as required by the rules of the U.S. Securities Exchange Commission with respect to non-GAAP financial measures (2021 results are presented also in 2022 constant currency exchange rates1) 2022 2021 2021(CC) The